ReNeuron Group plc Price (RENE.L)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

57,125,960

(0.2638)%

ReNeuron Performance History

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In ad... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $0.0-8.0
  • Market Cap 1.93M
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
  • IPO Date: August, 12, 2005
  • Country: GB
  • Currency: GBp
  • Headquaters: No Data
  • Employees: 26

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation